☰

Paul E. Clavijo, Ph.D. - Publications

Affiliations: 
2011 Cell Biology & Molecular Genetics University of Maryland, College Park, College Park, MD 
Area:
Molecular Biology, Cell Biology, Immunology
Tree Info Grants Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Asuzu DT, Alvarez R, Fletcher PA, Mandal D, Johnson K, Wu W, Elkahloun A, Clavijo P, Allen C, Maric D, Ray-Chaudhury A, Rajan S, Abdullaev Z, Nwokoye D, Aldape K, et al. Pituitary adenomas evade apoptosis via noxa deregulation in Cushing's disease. Cell Reports. 40: 111223. PMID 36001971 DOI: 10.1016/j.celrep.2022.111223  0.425
2022 Hu Z, Viswanathan R, Cheng H, Chen J, Yang X, Huynh A, Clavijo P, An Y, Robbins Y, Silvin C, Allen C, Ormanoglu P, Martin S, Cornelius S, Saleh A, et al. Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers. Molecular Cancer Research : McR. PMID 35176168 DOI: 10.1158/1541-7786.MCR-21-0624  0.369
2021 Valencia JC, Erwin-Cohen RA, Clavijo PE, Allen C, Sanford ME, Day CP, Hess MM, Johnson M, Yin J, Fenimore JM, Bettencourt IA, Tsuneyama K, Romero ME, Klarmann KD, Jiang P, et al. Myeloid derived suppressive cell expansion promotes melanoma growth and severity of autoimmunity by inhibiting CD40/IL-27 regulation in macrophages. Cancer Research. PMID 34642183 DOI: 10.1158/0008-5472.CAN-21-1148  0.344
2021 Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells. Journal For Immunotherapy of Cancer. 9. PMID 33741731 DOI: 10.1136/jitc-2020-002128  0.342
2020 Ye W, Gunti S, Allen CT, Hong Y, Clavijo PE, Van Waes C, Schmitt NC. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. Oncoimmunology. 9: 1710398. PMID 32002309 DOI: 10.1080/2162402X.2019.1710398  0.332
2019 Greene S, Robbins Y, Mydlarz WK, Huynh AP, Schmitt NC, Friedman J, Horn LA, Palena C, Schlom J, Maeda DY, Zebala JA, Clavijo PE, Allen C. Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK cell immunotherapy in head and neck cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31848188 DOI: 10.1158/1078-0432.CCR-19-2625  0.302
2019 Patel P, Sun L, Robbins Y, Clavijo PE, Friedman J, Silvin C, Van Waes C, Cook J, Mitchell J, Allen C. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. Oncoimmunology. 8: e1638207. PMID 31646086 DOI: 10.1080/2162402X.2019.1638207  0.366
2019 Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J, Allen CT. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. Jci Insight. 4. PMID 30944253 DOI: 10.1172/jci.insight.126853  0.341
2018 Das R, Coupar J, Clavijo PE, Saleh A, Cheng TF, Yang X, Chen J, Van Waes C, Chen Z. Lymphotoxin-β receptor-NIK signaling induces alternative RELB/NF-κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer. Molecular Carcinogenesis. PMID 30488488 DOI: 10.1002/mc.22938  0.362
2018 Sun L, Moore E, Berman R, Clavijo PE, Saleh A, Chen Z, Van Waes C, Davies J, Friedman J, Allen CT. WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. Oncoimmunology. 7: e1488359. PMID 30288354 DOI: 10.1080/2162402X.2018.1488359  0.351
2017 Davis RJ, Moore EC, Clavijo PE, Friedman J, Cash HA, Chen Z, Silvin C, Van Waes C, Allen CT. Anti-PD-L1 efficacy can be enhanced by inhibition of myeloid derived suppressor cells with a selective inhibitor of PI3Kδ/γ. Cancer Research. PMID 28364000 DOI: 10.1158/0008-5472.CAN-16-2534  0.364
2016 Moore EC, Clavijo PE, Davis R, Cash HA, Van Waes C, Kim YJ, Allen CT. Established T-cell inflamed tumors rejected after adaptive resistance was reversed by combination STING activation and PD-1-pathway blockade. Cancer Immunology Research. PMID 27821498 DOI: 10.1158/2326-6066.CIR-16-0104  0.349
Show low-probability matches.